Genmab A/S Stock Nasdaq
Stocks
GMAB
US3723032062
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe BZX
11:45:37 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 34.96 USD | +0.36% |
|
+0.52% | +13.38% |
| 09-24 | AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY in Follicular Lymphoma | MT |
| 09-24 | Hansa Biopharma brings in two new board members | FW |
| Market Cap | 136B 20.61B 18.13B 17.09B 15.59B 29.16B 1,978B 29.38B 205B 79.47B 1,007B 77.38B 75.7B 3,276B | P/E 2026 * |
28.3x | P/E 2027 * | 20.3x |
|---|---|---|---|---|---|
| Enterprise Value | 155B 23.52B 20.69B 19.51B 17.8B 33.28B 2,258B 33.54B 234B 90.71B 1,149B 88.32B 86.41B 3,740B | EV / Sales 2026 * |
5.34x | EV / Sales 2027 * | 4.36x |
| Free-Float |
94.3% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| GMAB | Delayed | |
CBOE
| GMAB | Real-time | |
|
Börse Stuttgart
| GE91 | Delayed | |
|
Tradegate
| GE91 | Real-time | |
|
Deutsche Boerse AG
| GE91 | Delayed | |
|
Boerse Muenchen
| GE91 | Real-time |
Last Transcript: Genmab A/S
| 1 day | +0.34% | ||
| 1 week | +0.52% | ||
| Current month | +5.31% | ||
| 1 month | +1.63% | ||
| 3 months | +33.59% | ||
| 6 months | +33.74% | ||
| Current year | +13.38% |
| 1 week | 34.36 |  | 35.66 |
| 1 month | 32.21 | | 35.66 |
| Current year | 23.62 | | 35.66 |
| 1 year | 23.62 | | 35.66 |
| 3 years | 17.24 | | 36.71 |
| 5 years | 17.24 | | 47.5 |
| 10 years | 12.1 | | 49.07 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 2010-05-31 | |
Anthony Pagano
DFI | Director of Finance/CFO | 48 | 2020-02-29 |
Rayne Waller
CTO | Chief Tech/Sci/R&D Officer | - | 2024-08-15 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2003-10-31 | |
| Director/Board Member | 58 | 2014-12-31 | |
| Director/Board Member | 75 | 2014-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.36% | +0.52% | - | - | 20.61B | |
| -3.30% | +1.19% | +54.62% | +104.15% | 71.94B | |
| +1.25% | -3.01% | +40.12% | +77.12% | 59.35B | |
| +2.12% | +5.79% | +32.63% | +24.27% | 27.16B | |
| -4.12% | -2.83% | -14.01% | +352.29% | 26.54B | |
| -0.38% | +2.67% | +0.55% | -4.36% | 24.93B | |
| +0.40% | +0.75% | +22.91% | -9.68% | 20.61B | |
| -1.70% | -3.35% | +146.86% | +325.69% | 15.03B | |
| +0.21% | +1.21% | -6.26% | +493.02% | 14.2B | |
| -0.33% | -0.98% | +49.37% | +164.73% | 14.36B | |
| Average | -0.54% | -0.12% | +36.31% | +169.69% | 30.46B | |
| Weighted average by Cap. | -0.80% | -0.24% | +36.99% | +131.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 28.99B 4.41B 3.88B 3.66B 3.34B 6.24B 423B 6.29B 43.87B 17B 215B 16.55B 16.19B 701B | 33.65B 5.12B 4.5B 4.24B 3.87B 7.24B 491B 7.3B 50.91B 19.73B 250B 19.21B 18.79B 813B |
| Net income | 4.97B 756M 665M 627M 572M 1.07B 72.59B 1.08B 7.53B 2.92B 36.95B 2.84B 2.78B 120B | 7.09B 1.08B 949M 895M 816M 1.53B 104B 1.54B 10.73B 4.16B 52.71B 4.05B 3.96B 172B |
| Net Debt | 19.17B 2.92B 2.56B 2.42B 2.21B 4.12B 280B 4.16B 29.01B 11.24B 142B 10.95B 10.71B 464B | 11.04B 1.68B 1.48B 1.39B 1.27B 2.37B 161B 2.39B 16.7B 6.47B 81.99B 6.3B 6.16B 267B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-25 | US$34.90 | +0.20% | 1,668,788 |
| 26-09-24 | US$34.83 | +0.23% | 2,514,937 |
| 26-09-23 | US$34.75 | -1.33% | 2,509,746 |
| 26-09-22 | US$35.22 | +1.53% | 2,297,611 |
| 26-09-21 | US$34.69 | -0.14% | 1,577,461 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
Select your edition
All financial news and data tailored to specific country editions
